ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics

    WELLESLEY HILLS, Mass., Feb. 25 /CNW/ -- Joseph F. Finn, Jr., CPA, the
Assignee for the Benefit of Creditors of ActivBiotics, as a result of growing
interest from prospective buyers, announced today a development strategy for
further advancement of the company's proprietary benzoxazinorifamycins as
leading antibacterial drug candidates in combination antibiotic therapy.
Rifalazil is the most developed of these compounds, though most of the
interest for combination antibiotics has centered on novel compounds or new
chemical entities ("NCEs").
    Combination antibiotic therapy has been used as the treatment of choice
for certain stubborn bacterial infections. Two prime examples are tuberculosis
and gastric ulcer disease, caused by Mycobacterium tuberculosis infection and
Helicobacter pylori infection, respectively. In both of these examples, the
rifamycins rifampin and rifabutin have been used because of their potency
against these pathogens. However, these rifamycins share the negative
attribute of eliciting drug-drug interactions; that is, they interfere with
the actions of many other medications that the patient may require. The NCEs
are breakthrough drug candidates because they have not been shown
preclinically to engender drug-drug interactions caused by the other
rifamycins. In addition the NCEs have equal or superior potency compared with
    There is increasing recognition that rifamycins (e.g. rifampin and ABI-
0043) are highly efficacious against implant-associated staphylococcal
infection. This property is due to their excellent efficacy against non-
growing and surface-adhering staphylococci. No other class of antimicrobial
agents shares this property. In view of the growing number of patients with
implants (artificial joints, internal fixation devices, vascular grafts etc.)
there is an urgent need for this type of antibiotic. "The development of an
NCE for combination antibiotic treatment could be extremely beneficial,"
commented Werner Zimmerli, M.D., a leading infectious disease clinician and
researcher at the University of Basel, Switzerland. "In our animal model for
implant-associated infections, which has proven to be clinically predictive of
combination antibiotic efficacy for the treatment of foreign body infections,
the NCE ABI-0043 was as effective as rifampin. The fact that ABI-0043 is not
predicted to have drug-drug interactions provides a very significant advantage
over rifampin, which cannot be given, for example, in patients with oral
anticoagulation due to dangerous interaction." In addition, based on their
antibacterial spectrum and potency against key pathogens, the NCEs may also be
developed for the treatment of bacterial endocarditis, osteomyelitis, acute
and chronic respiratory infections, gastrointestinal infections, and acne.
    The sale of ActivBiotics' assets, including rifalazil and the NCEs, is
being conducted through an Assignment for the Benefit of Creditors.  The
bidding for the assets, which may be purchased separately or in combination,
is scheduled for March 14, 2008.
    For additional information on the terms of sale and to obtain a bidder's
package, please contact Joseph F. Finn, Jr., CPA (,
phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201,
Wellesley Hills, MA  02481-3613. For technical information on the assets,
please contact Christo Shalish,

For further information:

For further information: For additional information on the terms of sale
 and to obtain a bidder's package, Joseph F. Finn, Jr., CPA +1-781-237-8840,; For technical information on the assets, Christo 
Shalish, Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890